Promising Clinical Developments in Rocket Pharmaceuticals Justify Buy Rating and $52 Target Price
Rocket Pharmaceuticals (RCKT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum ...
Promising Phase 1 Trial Data and Market Potential Propel Buy Rating for Rocket Pharmaceuticals’ RP-A501 Gene Therapy
Jason Zemansky, an analyst from Bank of America Securities, reiterated the Buy rating on Rocket Pharmaceuticals (RCKT – Research Report). The ...
Forget driverless cars. One company wants autonomous helicopters to spray crops and fight fires
Rotor has built two autonomous Sprayhawks and aims to have as many as 20 ready for market next year. The company also is developing helicopters that would carry cargo in disaster zones and to offshore ...